

1 **Antimicrobial susceptibility patterns of respiratory Gram-negative**  
2 **bacterial isolates from COVID-19 patients in Switzerland**

3 *Marina Gysin<sup>1\*</sup>, Claudio Tirso Acevedo<sup>2\*</sup>, Klara Haldimann<sup>1\*</sup>, Elias Bodendoerfer<sup>1</sup>, Frank*  
4 *Imkamp<sup>1</sup>, Karl Bulut<sup>1</sup>, Philipp Karl Buehler<sup>3</sup>, Silvio Daniel Brugger<sup>2</sup>, Katja Becker<sup>1</sup>, Sven N.*  
5 *Hobbie<sup>1\*\*</sup>*

6 <sup>1</sup> *Institute of Medical Microbiology, University of Zurich, Gloriastrasse 30, 8006 Zurich, Switzerland*

7 <sup>2</sup> *Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich,*  
8 *Raemistrasse 100, 8091 Zurich, Switzerland*

9 <sup>3</sup> *Institute for Intensive Care Medicine, University Hospital Zurich and University of Zurich, Raemistrasse 100,*  
10 *8091 Zurich, Switzerland*

11 *\*MG, CTA, and KH contributed equally to this study; \*\*correspondence: sven.hobbie@uzh.ch*

12 **Corresponding author:**

13 Dr. Sven Hobbie  
14 University of Zurich  
15 Institute of Medical Microbiology  
16 Gloriastrasse 30  
17 CH-8006 Zurich  
18 Phone +41 44 634 22 84  
19 E-mail: sven.hobbie@uzh.ch

20

21

22

23

24

25 **ABSTRACT**

26 **Background**

27 Bacterial superinfections associated with COVID-19 are common in ventilated ICU patients and impact  
28 morbidity and lethality. However, the contribution of antimicrobial resistance to the manifestation of  
29 bacterial infections in these patients has yet to be elucidated.

30 **Methods**

31 We collected 70 Gram-negative bacterial strains, isolated from the lower respiratory tract of  
32 ventilated COVID-19 patients in Zurich, Switzerland between March and May 2020. Species  
33 identification was performed using MALDI-TOF; antibiotic susceptibility profiles were determined by  
34 EUCAST disk diffusion and CLSI broth microdilution assays. Selected *Pseudomonas aeruginosa* isolates  
35 were analyzed by whole-genome sequencing.

36 **Results**

37 *P. aeruginosa* (46%) and *Enterobacterales* (36%) comprised the two largest etiologic groups. Drug  
38 resistance in *P. aeruginosa* isolates was high for piperacillin/tazobactam (65.6%), cefepime (56.3%),  
39 ceftazidime (46.9%) and meropenem (50.0%). *Enterobacterales* isolates showed slightly lower levels  
40 of resistance to piperacillin/tazobactam (32%), ceftriaxone (32%), and ceftazidime (36%). All  
41 *P. aeruginosa* isolates and 92% of *Enterobacterales* isolates were susceptible to aminoglycosides, with  
42 apramycin found to provide best-in-class coverage. Genotypic analysis of consecutive *P. aeruginosa*  
43 isolates in one patient revealed a frameshift mutation in the transcriptional regulator *nalC* that  
44 coincided with a phenotypic shift in susceptibility to  $\beta$ -lactams and quinolones.

45 **Conclusions**

46 Considerable levels of antimicrobial resistance may have contributed to the manifestation of bacterial  
47 superinfections in ventilated COVID-19 patients, and may in some cases mandate consecutive  
48 adaptation of antibiotic therapy. High susceptibility to amikacin and apramycin suggests that  
49 aminoglycosides may remain an effective second-line treatment of ventilator-associated bacterial  
50 pneumonia, provided efficacious drug exposure in lungs can be achieved.

51

52

53

54

55 **KEYWORDS**

56 COVID-19, superinfection, ventilator-associated bacterial pneumonia, antimicrobial resistance,  
57 aminoglycoside, apramycin

58

## 59 BACKGROUND

60 The emergence of the coronavirus disease 2019 (COVID-19) has resulted in high rates of intensive care  
61 unit (ICU) admissions of critically ill patients [1] suffering from acute respiratory distress syndrome  
62 (ARDS) [2,3]. Respiratory viral infections predispose patients to secondary bacterial infections which  
63 are associated with increased morbidity and case fatality rates [4,5]. Particularly, secondary bacterial  
64 infections acquired in the setting of ICU-treatment are also independently associated with higher risk  
65 of mortality when compared with community-acquired infections [6].

66 Secondary bacterial infections in COVID-19 patients, hereafter referred to as superinfections, have not  
67 been intensively investigated thus far. Yet, mainly small cohort studies have reported high  
68 superinfection rates in critically ill and/or deceased COVID-19 patients. For instance, a retrospective  
69 cohort study by Zhou *et al.* documented secondary infections in 50% of deceased COVID-19 patients  
70 and ventilator-associated pneumonia (VAP) in a third of mechanically ventilated patients, despite the  
71 fact that 95% of patients received antibiotic treatment [7]. A study by Du *et al.* described secondary  
72 bacterial infections at a late stage of disease in 10 of 21 deceased patients with the etiological  
73 spectrum including *Klebsiella pneumoniae*, *Staphylococcus spp.*, *Acinetobacter baumannii* and  
74 *Escherichia coli* [8]. However, a comprehensive antimicrobial resistance (AMR) surveillance of  
75 bacterial superinfection in critically ill COVID-19 patients treated in the ICU has yet to be reported.

76 In recent years, the incidence of infections caused by gram-negative bacilli (GNB), especially  
77 multidrug-resistant (MDR) organisms, in highly susceptible ICU patients has increased [9,10].  
78 Particularly infections caused by MDR GNB are associated with a substantial risk of morbidity and in-  
79 hospital mortality for the critically ill [6]. The increased exposure of patients to antimicrobials and the  
80 global surge in hospital and especially ICU admissions due to the COVID-19 pandemic are rising  
81 concerns on the long-term impact on AMR in the acute care setting [11–13]. During the beginning of  
82 the COVID-19 pandemic, uncertainty regarding the novel disease has resulted in high antibiotic use  
83 since empirical antibiotic treatment was commonly prescribed before or at the time of hospital  
84 admission. A meta-analysis by Rawson *et al.* revealed that 72% of hospitalized patients received  
85 antimicrobial therapy despite low initial evidence of community-acquired co-infections at that time  
86 [14]. Similarly, the ISARIC WHO Clinical Characterization Protocol reported preceding anti-infective  
87 treatment in 76.6% of hospitalized patients [15].

88 A detailed understanding of the epidemiology and AMR pattern of bacterial superinfections in  
89 critically ill COVID-19 patients is urgently needed for adequate treatment. Here we report the bacterial  
90 spectrum and the antimicrobial susceptibility patterns of respiratory GNB isolated from ventilated ICU  
91 patients during the first COVID-19 wave in Switzerland. In addition, we investigate changes in the  
92 antimicrobial resistance over time for a single *P. aeruginosa* infection under antibiotic therapy using  
93 whole-genome sequencing (WGS).

94

## 95 **METHODS**

### 96 **Study population**

97 This study was conducted within the MicrobiotaCOVID cohort, a single-center, prospective  
98 observational study conducted at the University Hospital Zurich, Switzerland. The study was approved  
99 by the Local Ethics Committee of the Canton of Zurich, Switzerland (Kantonale Ethikkommission Zurich  
100 BASEC ID 2020 – 00646). All patients with confirmed SARS-CoV-2 infection admitted to the ICU  
101 requiring mechanical ventilation between March and May 2020 were included ( $n = 40$ ). SARS-CoV-2  
102 was detected by real-time RT-PCR as previously described [16]. Informed consent of all patients was  
103 obtained. The study cohort during this time period has been described recently [17].

### 104 **Sample collection**

105 Longitudinal sample collection, processing and testing was performed as described recently [17]. In  
106 brief, the following sampling was performed: If the clinical situation allowed, bronchoalveolar lavages  
107 (BAL) with 10ml of saline were collected by the ICU personnel upon ICU admission and during the later  
108 course of the disease if clinically indicated. Tracheobronchial secretions (TBS) were collected from  
109 each intubated patient at least on day 0 (i.e., upon ICU admission), day 1, day 2, day 3, day 5 and  
110 henceforth every 5 days. If the clinical situation as determined by the ICU attending physician did not  
111 allow TBS collection, no sampling was performed. Samples were initially processed at the diagnostic  
112 laboratory of the Institute of Medical Microbiology (IMM) in the course of routine diagnostics. Species  
113 identification was performed with MALDI-TOF MS (Bruker Daltonics, Bremen, Germany) using the  
114 direct formic acid transfer method [18]. Repetitive detected isolates of the same species in the same  
115 patients were included to monitor changes in antimicrobial susceptibility over time.

### 116 **Antimicrobial susceptibility testing (AST)**

117 Bacterial isolates were inoculated onto Columbia sheep blood (COS) agar and were incubated for 24  
118 hours prior to antimicrobial susceptibility testing. The European Committee on Antimicrobial  
119 Susceptibility Testing (EUCAST) disk diffusion method (version 8.0, January 2020) [19] was applied to  
120 determine the isolate's antimicrobial susceptibility to piperacillin/tazobactam (TPZ36),  
121 amoxicillin/clavulanate (AMC30), ceftriaxone (CRO30), cefepime (FEP30), meropenem (MEM10),  
122 amikacin (AK30), tobramycin (TOB10), gentamicin (CN10), trimethoprim/sulfamethoxazole (SXT25)  
123 ceftazidime (CAZ10) and ciprofloxacin (CIP5). The antibiotic SirScan Disks were obtained from i2a  
124 Diagnostics, Montpellier, France. Interpretative criteria in the EUCAST guidelines 2020 [20] were  
125 applied to set clinical resistance breakpoints and translate inhibition zone diameters into either  
126 resistant (R) or non-resistant (susceptible, S and "susceptible, increased exposure" (intermediate), I)  
127 phenotypes. Interpretative criteria for *P. aeruginosa* resistance to GEN were derived from the EUCAST  
128 guidelines 2019 [21] instead, since they have been removed from the 2020 version. Interpretative  
129 criteria for *Burkholderia cenocepacia* resistance to MEM and SXT (Table S4) were derived from the  
130 Clinical and Laboratory Standards Institute (CLSI) guidelines 2020 [22].

131 Antimicrobial susceptibilities were further assessed by broth microdilution assays following the CLSI  
132 guidelines [22,23]. Interpretative criteria in the EUCAST guidelines 2020 were followed to set clinical  
133 breakpoints and translate MICs into drug susceptibility. Interpretative criteria for *P. aeruginosa*  
134 resistance to GEN were derived from the EUCAST guidelines 2019 instead, since they have been

135 removed from the 2020 version. For the aminoglycoside plazomicin, the FDA-identified interpretative  
136 criteria of 2, 4, and  $\geq 8$  mg/L were used for susceptible, intermediate, and resistant, respectively [24].

137 The minimal inhibitory concentration (MIC) performance standard for the aminoglycoside apramycin  
138 was set to a modal value of 4 mg/L for *E. coli* ATCC 25922 and an acceptable range of 2-8 mg/L.  
139 Epidemiological cut-off values (ECOFFs) of 8 mg/L for *Enterobacterales* and 16 mg/L for *P. aeruginosa*  
140 were used as interpretative criteria [25].

#### 141 **Whole-Genome Sequencing of selected *P. aeruginosa* isolates**

142 Whole-genome sequencing was applied to detect resistance determinants of eight selected  
143 consecutive *P. aeruginosa* isolates from a single patient.

144 DNA was extracted from cultures of the clinical isolates grown on Columbia sheep blood (COS) agar  
145 plates using the DNeasy® UltraClean® Microbial kit (Qiagen, Hilden, Germany) according to the  
146 manufacturer's recommendations. Library preparation was performed using the Qiagen® QIAseq FX  
147 DNA kit (Qiagen, Hilden, Germany), according to manufacturer's instructions. Sequencing library  
148 quality and size distribution were analyzed on a fragment analyzer automated CE system (Advanced  
149 Analytical Technologies Inc., Heidelberg, Germany), using the fragment analyzer 474 HS next  
150 generation sequencing (NGS) kit. Sequencing libraries were pooled in equimolar concentrations and  
151 paired-end sequenced (2 × 150 bp) on an Illumina MiSeq platform (Illumina®, San Diego, CA, USA).

152 Raw sequencing reads (FASTQ) were filtered and trimmed using Trimmomatic [26]. CONTIGS were  
153 assembled from processed FASTQ files using SPAdes (v3.13.0). To identify antibiotic resistance  
154 determinants CONTIGS were analyzed using the command line version of Resistance Gene Identifier  
155 (RGI; v4.2.2) and CARD (Comprehensive Antibiotic Resistance Database, v3.1.0) [27,28].

156

157


158 **RESULTS**

159 **Species distribution**

160 Out of a total of 314 respiratory samples (289 TBS and 25 BAL) 168 GNB isolates were detected, in 19  
161 of the 40 patients (48%). A representative subset of 70 GNB, including repetitive isolates from 17  
162 patients, were further analyzed in this study. More information about the 17 patients is provided in  
163 the Supplementary Information (Table S1).

164 The two largest groups of pathogens in our panel of COVID-19 GNB isolates were *Pseudomonas*  
165 *aeruginosa* (46%) and *Enterobacterales* (36%). *Burkholderia cenocepacia* (17%) was found in smaller  
166 numbers, as well as a single *Acinetobacter bereziniae* isolate (Figure 1A). Within the order of  
167 *Enterobacterales*, *Enterobacter cloacae* (32%) and *Klebsiella pneumoniae* (28%) were the two  
168 predominant species, followed by *Klebsiella aerogenes* (20%), *Citrobacter spp.* (16%), and  
169 *Escherichia coli* (4%) (Figure 1B). The species distribution of the analyzed subset ( $n = 70$ ) was shown  
170 to be representative for all the identified Gram-negative isolates of the MicrobiotaCOVID cohort  
171 ( $n = 168$ , Figure S1).

172



**Figure 1. Subset distribution of all Gram-negative respiratory isolates studied (a) and further differentiation within the order of *Enterobacterales* (b).**

173

174

175

## 176 Antimicrobial susceptibility patterns

177 The antimicrobial susceptibility profile of all *Enterobacterales* and *P. aeruginosa* isolates ( $n = 57$ ) was  
178 determined by the EUCAST disk diffusion method (Figure 2, Table S2).

179 A high proportion of *P. aeruginosa* isolates was found to be resistant to the standard-of-care  
180 antibiotics cefepime (FEP, 56.3%), ceftazidime (CAZ, 46.9%), and meropenem (MEM, 50.0%).  
181 *P. aeruginosa* resistance to piperacillin/tazobactam (TZP, 65.6%) was the highest for any of the  
182 relevant drugs tested in this study. Resistance to ciprofloxacin (CIP) was comparatively low in  
183 *P. aeruginosa* isolates (15.6%).


184 *Enterobacterales* isolates showed likewise resistance to TZP (32.0%), ceftriaxone (CRO, 32.0%), and  
185 CAZ (36.0%). The *Enterobacterales* resistance was lower for FEP (8.0%) and  
186 trimethoprim/sulfamethoxazole (SXT, 4.0%).

187 Disk diffusion further revealed all the *P. aeruginosa* isolates to be susceptible to gentamicin (GEN),  
188 tobramycin (TOB), and amikacin (AMI). Aminoglycoside susceptibility was also high for the  
189 *Enterobacterales* isolates with only a single *E. coli* isolate lacking susceptibility to gentamicin and  
190 tobramycin.

191 To study the antimicrobial susceptibility profiles in more detail and to test additional antibiotics not  
192 routinely included in the disk diffusion panel, the clinical isolates were also analyzed by broth  
193 microdilution assays to determine the minimal inhibitory concentration (MIC) (Figure 3, Table S3). For  
194 those drugs tested by both disk diffusion and broth microdilution, the results correlated well between  
195 the two methodologies (Figure S2 and S3).


196 Broth microdilution assays confirmed the results of the disk diffusion assay with regards to high  
197 aminoglycoside susceptibility of both *P. aeruginosa* and *Enterobacterales* and extended the  
198 aminoglycoside panel by including plazomicin (PLZ) and apramycin (APR). Both PLZ and APR showed  
199 full coverage of *Enterobacterales*. Apramycin additionally showed full coverage of *P. aeruginosa*  
200 (Figure 3, Table S3).

201



**Figure 2. Inhibition zone diameter distributions for respiratory *Enterobacteriales* and *P. aeruginosa* isolates from ventilated COVID-19 patients.** Vertical dashed lines indicate the EUCAST clinical resistant breakpoint values for piperacillin/tazobactam (TZP), cefepime (FEP), ceftazidime (CAZ), meropenem (MEM), ciprofloxacin (CIP), gentamicin (GEN), tobramycin (TOB), amikacin (AMI), amoxicillin/clavulanate (AMC), ceftriaxone (CRO) and trimethoprim/sulfamethoxazole (SXT) for *Enterobacteriales* (orange) and *P. aeruginosa* (blue) isolates, respectively.





**Figure 3. Minimal inhibitory concentration (MIC) distributions for respiratory *Enterobacterales* and *P. aeruginosa* isolates from ventilated COVID-19 patients.** Vertical dashed lines indicate the EUCAST clinical resistant breakpoint values for piperacillin/tazobactam (TZP), cefepime (FEP), meropenem (MEM), gentamicin (GEN), tobramycin (TOB), amikacin (AMI) and trimethoprim/sulfamethoxazole (SXT) for *Enterobacterales* (orange) and *P. aeruginosa* (blue) isolates, respectively. In the case of plazomicin (PLZ), the vertical dashed line indicates the FDA-identified interpretative criteria. In the case of APR (apramycin), vertical dashed lines indicate the proposed ECOFF values [25].

203


204

## 205 **Antibiotic resistance development in *P. aeruginosa* under antimicrobial selection pressure**

206 Next, we analyzed bacterial isolates that were repetitively derived from individual patients to study  
207 changes to antimicrobial susceptibility in response to antibiotic therapy. A decrease in antimicrobial  
208 susceptibility over the course of treatment was particularly pronounced for *P. aeruginosa* (Figure S4).  
209 This prompted us to select a single *P. aeruginosa* infection for the analysis of phenotypic and genotypic  
210 changes in response to antibiotic therapy across eight consecutive isolates collected on day 9, 10, 16,  
211 17, 18, 22, 29 and 37 (Figure 4).

212 The patient was initially admitted to the ICU of a regional hospital due to severe COVID-19 pneumonia.  
213 He had to be intubated and mechanically ventilated because of respiratory failure. After 2 days the  
214 patient was referred to the ICU of the University Hospital Zurich, a tertiary care hospital, because of  
215 pulmonary deterioration and worsening of inflammatory parameters and empiric antibiotic therapy  
216 for hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) was started with  
217 piperacillin/tazobactam. At this point, the patient had developed severe ARDS (oxygenation index 85  
218 mmHg). Initial isolation of *Pseudomonas aeruginosa* from TBS occurred shortly after on day 4 after  
219 ICU admission (Figure S4, ID 05). After seven days of antibiotic therapy with piperacillin/tazobactam  
220 (TZP) resistance was not only detected against this broad-spectrum  $\beta$ -lactam antibiotic/ $\beta$ -lactamase  
221 inhibitor combination, but also against third and fourth generation cephalosporins (CAZ and FEP)  
222 (Figure 4). Consecutively, antibiotic therapy was switched to meropenem (MEM) and subsequent  
223 isolates (isolates 2 and 3) yet again showed susceptibility to TZP and cephalosporins (CAZ and FEP).  
224 After eight days of antibiotic therapy with MEM, repetitive isolates showed resistance to MEM  
225 (isolates 4 to 8) and eventually to TZP as well as extended-spectrum cephalosporins (CAZ and FEP),  
226 indicating a multidrug-resistant gram-negative (MDRGN) infection. In the meantime, the patient  
227 showed clinical improvement and had been successfully weaned from the respirator. Despite elevated  
228 inflammatory parameters the antimicrobial treatment was stopped for an antibiotics-free period. 2  
229 days after stopping the antibiotic therapy, purulent endotracheal aspiration was obtained and therapy  
230 with ciprofloxacin (CIP) was initiated and continued for 9 days. Gentamicin was added because of  
231 pulmonary deterioration (Figure 4 and Figure S4, ID 05). Due to ongoing deterioration and after  
232 resistance to fluoroquinolones including CIP occurred, antibiotic therapy was switched to  
233 ceftazidime/avibactam (CZA) for a total of 11 days. Under antibiotic therapy with CZA the patient  
234 showed again clinical improvement but *P. aeruginosa* was still detectable throughout antibiotic  
235 treatment. Eventually the patient was successfully extubated on day 40 after initial ICU admission and  
236 intubation. Therapy with inhaled tobramycin (TOB) was started 2 days before extubation but was  
237 stopped again after a total of 6 days, as *P. aeruginosa* was still detectable and the patient showed no  
238 signs of acute infection, thus indicating ongoing colonization of the patient with MDR *P. aeruginosa*.

239 Finally, we performed whole-genome sequencing of the eight consecutive isolates in an attempt to  
240 detect possible resistance determinants that may explain the phenotypic progression (Excel file S1).  
241 Whole-genome analysis indicated that all eight isolates originated from the same clone indeed. The  
242 clone was characterized by two  $\beta$ -lactamases that commonly occur in *P. aeruginosa*: an OXA-50 like  
243 type and PDC-91. A 1-bp deletion causing a frameshift in the gene encoding the transcriptional  
244 regulator NaC of the *mexAB-oprM* multidrug efflux pump operon was found in isolates 4 till 8, but  
245 was absent in the first three isolates, providing a rationale for the drop in susceptibility from day 17  
246 onwards (Figure 4).



**Figure 4. Antibiotic resistance development of *P. aeruginosa* in a single patient during antibiotic therapy.** (a) The disc diffusion inhibition zones for piperacillin/tazobactam (TZP), meropenem (MEM), ciprofloxacin (CIP), ceftazidime (CAZ), cefepime (FEP), tobramycin (TOB) and gentamicin (GEN) are shown for eight consecutive isolates (labeled from 1-8), collected after 9, 10, 16, 17, 18, 22, 29 and 37 days of ICU admission. Horizontal dashed lines indicate the EUCAST clinical resistant breakpoint values for TZP (18mm), MEM (18mm), CIP (26mm), CAZ (17mm), FEP (21mm), TOB (18mm) and GEN (15mm), respectively. The bracket describes the resistance determinant detected in the *P. aeruginosa* isolates by whole-genome sequencing. (b) Antibiotic therapy of the patient. Piperacillin/tazobactam (TZP), meropenem (MEM), ciprofloxacin (CIP), gentamicin (GEN), ceftazidime/avibactam (CZA) and tobramycin (TOB).

247

248

## 249 DISCUSSION

250 This study belongs to a group of early microbiological studies that report a detailed antimicrobial  
251 susceptibility profiling of Gram-negative bacterial superinfections in ventilated COVID-19 patients. The  
252 sample size is limited and has a strong geographic bias, but some important conclusions can  
253 nevertheless be drawn and will add to a growing number of similar studies that we expect from other  
254 geographic locations.

255 The etiology found here for late-onset VAP in COVID-19 patients resembles the diversity of Gram-  
256 negative pathogens typically found in nosocomial pneumonia [29]. Previous cohort studies have  
257 reported diverse etiology in COVID-19 confirmed cohorts, with *A. baumannii*, *K. pneumoniae*, *E. coli*  
258 and *P. aeruginosa* as predominant infecting agents [30–32].

259 Besides *P. aeruginosa* and *Enterobacterales*, *Burkholderia cenocepacia* were the third most common  
260 isolates encountered in this study. The latter is regarded a natural colonizer and an opportunistic  
261 pathogen in immune-compromised patients, with a naturally high intrinsic resistance to various  
262 antibiotics [33]. Trimethoprim-sulfamethoxazole (SXT) is used as a first-line option for the  
263 suppression/control of the infection. Since we only had a small number of *B. cenocepacia* isolates in  
264 our study, all of which were susceptible to SXT (Table S4), we decided to focus further analysis on only  
265 *P. aeruginosa* and *Enterobacterales*.

266 *P. aeruginosa* represents a notorious pathogen of nosocomial infections often characterized by MDR,  
267 especially in VAP and cystic fibrosis patients [34,35]. Treatment success is greatly hampered due to its  
268 intrinsic and adaptive resistance to nearly all available antipseudomonal agents. Important  
269 determinants driving resistance in *P. aeruginosa* are multidrug efflux pumps, alterations to its outer  
270 membrane porins, and the expression of  $\beta$ -lactamases [36]. For the *P. aeruginosa* isolates analyzed  
271 here, we found very high levels of drug resistance to TZP, FEP, CAZ and MEM.

272 For the *Enterobacterales* isolates we found a relatively high level of resistance to TZP, CRO, CAZ, and  
273 AMC. This may be explained by prior selection related to early antibiotic treatment in the course of  
274 COVID-19 infection, since AMC, CRO, and TZP are commonly used in Switzerland as first-line drugs for  
275 nosocomial bacterial pneumonia. Some of the species within the order of *Enterobacterales* are further  
276 characterized by a chromosomally encoded AmpC  $\beta$ -lactamase, which also contributes to decreased  
277 susceptibility to selected  $\beta$ -lactam antibiotics and in particular AMC [37]. The high resistance of  
278 *Enterobacterales* to amoxicillin/clavulanate (AMC, 72.0%) was not surprising considering intrinsic  
279 (chromosomal) AmpC genes of *E. cloacae*, *K. aerogenes*, and *C. freundii* [37]. *Enterobacterales*  
280 resistance to FEP, SXT, MEM and aminoglycosides was low or absent in comparison to the  
281 aforementioned antibiotics. Only a single *E. coli* isolate (Figure 2 and 3 and Figure S2), showed  
282 resistance to gentamicin and tobramycin, without prior exposure to aminoglycosides in the patient's  
283 treatment regimen.

284 Our findings seem to be generally aligned with those of several other reports from countries that  
285 experienced a high incidence of severe COVID-19 cases, which proposed an increase in MDR bacterial  
286 infections in severely ill COVID-19 patients [32,38–41]. However, it is conceivable to assume that the  
287 species distribution and specific resistance patterns within individual studies may vary depending on  
288 the geographic and local ICU etiology of resistant isolates, study-specific patient recruitment and

289 sample selection, and the treatment history of prior antibiotic exposure in regular VAP patients and  
290 COVID-19 patients.

291 There is no evidence to assume that the antimicrobial resistance rates in ventilated COVID-19 patients  
292 differ significantly from resistance rates from non-COVID-19 ventilated ICU patients and underlie  
293 mainly local ICU epidemiology. Surveillance of MDR infections in ventilated ICU patients during and  
294 after the COVID-19 pandemic is required to adequately monitor a putative increased incidence of MDR  
295 infections in this specific patient population.

296 In the present study, antibiotic resistance levels seemed to increase over the course of antibiotic  
297 treatment in the *P. aeruginosa* isolates (Figure 4 and Figure S4). Resistance to TZP but also to third-  
298 and fourth-generation cephalosporins (CAZ and FEP, respectively) occurred on day 7 of TZP therapy  
299 as reflected in isolate 1 (Figure 4). This may be attributable to the two  $\beta$ -lactamases (OXA-50 like type  
300 and PDC-91) which were identified by WGS in all eight isolates from that single infection. The OXA-50  
301 like type enzyme is a class D  $\beta$ -lactamase, which has a reported narrow hydrolyzing spectrum including  
302 piperacillin but not meropenem [42]. PDC-91 is an inducible AmpC-like  $\beta$ -lactamase conferring  
303 resistance to broad-spectrum cephalosporins [43]. Surprisingly, we observed a completely susceptible  
304 phenotype in isolates 2 and 3. We hypothesize that these two isolates were colonizing a different  
305 niche in the airway tract, potentially with the formation of a biofilm, which could have limited  
306 antibiotic exposure and resulted in a sensitive phenotype in the disc diffusion assay.

307 The MexAB-OprM efflux pump is a clinically relevant efflux system in *P. aeruginosa* [37,44].  
308 Transcription of the corresponding genes is under regulation of MexR, NalC and NalD. Overexpression  
309 of this efflux pump can be induced by mutations in *nalC*, leading to resistance against  $\beta$ -lactams  
310 (except imipenem) and quinolones but not aminoglycosides [45].

311 WGS analysis identified a 1-bp deletion in the suppressor gene *nalC* of isolates 4 – 8, which likely  
312 renders the corresponding protein non-functional and eventually results in over-expression of MexAB-  
313 OprM. Notably, at the same time we observed a gradual to massive decrease in TZP, CAZ, FEP, CIP and  
314 MEM susceptibility in the consecutive isolates (Figure 4), indicating the importance of the *nalC*  
315 mutation in developing the MDR phenotype of isolate 8. However, imipenem has been described as  
316 unaffected by the MexAB-OprM efflux pump [45]. Hence, the observed resistance to imipenem  
317 (Figure S4, ID 05) may be caused by a different resistance mechanism. In addition, expression levels  
318 of *mexAB-oprM* or of *oxa-485* and *pdv-91* have not been tested, therefore the precise correlation of  
319 each drug susceptibility to its resistance mechanism remains to be investigated. Nevertheless, the  
320 detected resistance determinants in combination with the antibiotic treatment history provide a  
321 rational explanation for the emergence of this MDR *P. aeruginosa* strain.

322 In the case of pneumonia, a main determinant of antibiotic efficacy is the drug concentration in the  
323 lung parenchyma tissue. Although intravenous aminoglycosides penetrate in lung parenchyma and  
324 bronchial secretions, measured lung tissue concentrations have been found to be relatively low for  
325 some aminoglycosides, because plasma concentrations are kept low in clinical care to avoid systemic  
326 toxicity [46]. While therapy with inhaled aminoglycosides are well described and tolerated in the  
327 treatment of cystic fibrosis, administration of nebulized aminoglycosides in acute pulmonary  
328 infections has largely remained an off-label domain and requires further evaluation [47]. Our results  
329 warrant further exploration of inhaled aminoglycosides as a critical component in the treatment of  
330 HAP/VAP with MDR GNB in COVID-19 patients. The drug candidate apramycin, currently in clinical

331 development, has previously been suggested to have best-in-class coverage of drug-resistant GNB  
332 [25,48–50], which was confirmed for VAP bacterial isolates from COVID-19 superinfections here.

333

## 334 CONCLUSION

335 In conclusion, resistance to first-line antibiotics was prevalent in bacterial isolates from ventilated  
336 COVID-19 patients in Switzerland during the first wave of COVID-19. It is conceivable that AMR plays  
337 a key role in those ventilated patients that contract a VAP despite empiric treatment, and contributes  
338 to morbidity and case fatality rates of patients that in addition to COVID-19 treatment are likely to  
339 receive multi-drug regimens of second-line or last-resort antibiotics to control the bacterial infection.  
340 Aminoglycosides have regained interest as potent broad-spectrum antibiotics in the face of  $\beta$ -lactam  
341 and specifically carbapenem resistance, and represent a treatment option less toxic than polymyxins.  
342 In the present study, Aminoglycosides were the most effective drug class *in-vitro* for the respiratory  
343 clinical isolates studied here, and the only drug class with full coverage of all *P. aeruginosa* isolates.  
344 However, given the relatively low pulmonary tissue penetration and the potential risk of adverse  
345 effects at higher dosing, their clinical utility including alternative ways of administration, such as  
346 inhalation, will need to be further evaluated in clinical trials for use in patients with resistance to  
347 second-line therapies.

348

## 349 LIST OF ABBREVIATIONS

350	AMI	Amikacin
351	AMC	Amoxicillin/clavulanate
352	APR	Apramycin
353	AST	Antimicrobial Susceptibility Testing
354	CIP	Ciprofloxacin
355	CLSI	Clinical and Laboratory Standards Institute
356	CRO	Ceftriaxone
357	CST	Colistin
358	CAZ	Ceftazidime
359	CZA	Ceftazidime/avibactam
360	ECOFF	Epidemiological Cutoff
361	EUCAST	European Committee on Antimicrobial Susceptibility Testing
362	FEP	Cefepime
363	GEN	Gentamicin
364	GNB	Gram-negative bacilli
365	MEM	Meropenem
366	MIC	Minimal Inhibitory Concentration
367	PLZ	Plazomicin
368	SXT	Trimethoprim/sulfamethoxazole
369	TOB	Tobramycin
370	TZP	Piperacillin/tazobactam

371

372 **DECLARATIONS**

373 **Ethics approval and consent to participate:** The study was approved by the Local Ethics Committee  
374 of the Canton of Zurich, Switzerland (Kantonale Ethikkommission Zurich BASEC ID 2020 – 00646). All  
375 necessary patient/participant consent has been obtained and the appropriate institutional forms have  
376 been archived.

377 **Consent for publication:** All necessary patient/participant consent has been obtained and the  
378 appropriate institutional forms have been archived.

379 **Availability of data and material:** Data generated or analyzed during this study are included in this  
380 published article and its supplementary information files. The genome sequencing files generated and  
381 analyzed during the current study are available from the corresponding author on reasonable request.

382 **Competing interests:** Author SNH is a shareholder in Juvabis AG. All other authors declare no  
383 competing interests.

384 **Funding:** This study was partially funded by Innosuisse (project no. 45893.1 INNO-LS). The work was  
385 supported by the Clinical Research Priority Program of the University of Zurich for the CRPP Precision  
386 medicine for bacterial infections; and by the University of Zurich, Institute of Medical Microbiology.  
387 SDB is supported by a Fellowship from the Promedica Foundation (1449/M). The funders had no role  
388 in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

389 **Authors' contributions:** All authors contributed to the study conception and design. Material  
390 preparation, data collection and analysis were performed by Marina Gysin, Claudio Tirso Acevedo,  
391 Klara Haldimann, Elias Bodendoerfer, Frank Imkamp, Karl Bulut, Katja Becker, and Sven N. Hobbie. The  
392 first draft of the manuscript was written by Marina Gysin and all authors commented on previous  
393 versions of the manuscript. All authors read and approved the final manuscript.

394 **Acknowledgements:** The authors would like to express their gratitude to Reinhard Zbinden, Annelies  
395 Zinkernagel and the diagnostic laboratory staff of the Institute of Medical Microbiology for their  
396 support in accessing the bacterial clinical isolates, in performing MALDI-TOF and disk diffusion  
397 assays, whole-genome sequencing, and in accessing anonymized clinical information. We would like  
398 to acknowledge special permit by the University of Zurich to conduct research at the university labs  
399 during the COVID-19 lockdown period.

400

401

## 402 REFERENCES

- 403 1. Robertson LC, Al-Haddad M. Recognizing the critically ill patient. *Anaesthesia & Intensive Care*  
404 *Medicine*. 2013;14:11–4.
- 405 2. Armstrong RA, Kane AD, Cook TM. Outcomes from intensive care in patients with COVID-19: a  
406 systematic review and meta-analysis of observational studies. *Anaesthesia*. 2020;75:1340–9.
- 407 3. Phua J, Weng L, Ling L, Egi M, Lim C-M, Divatia JV, et al. Intensive care management of coronavirus  
408 disease 2019 (COVID-19): challenges and recommendations. *Lancet Respir Med*. 2020;8:506–17.
- 409 4. Hanada S, Pirzadeh M, Carver KY, Deng JC. Respiratory Viral Infection-Induced Microbiome  
410 Alterations and Secondary Bacterial Pneumonia. *Front Immunol*. 2018;9:2640.
- 411 5. Morens DM, Taubenberger JK, Fauci AS. Predominant Role of Bacterial Pneumonia as a Cause of  
412 Death in Pandemic Influenza: Implications for Pandemic Influenza Preparedness. 2009;16.
- 413 6. Vincent J-L, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, et al. Prevalence and  
414 Outcomes of Infection Among Patients in Intensive Care Units in 2017. *JAMA*. 2020;323:1478–87.
- 415 7. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult  
416 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 2020;395:1054–  
417 62.
- 418 8. Du R-H, Liang L-R, Yang C-Q, Wang W, Cao T-Z, Li M, et al. Predictors of mortality for patients with  
419 COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. *Eur Respir J*.  
420 2020;55:2000524.
- 421 9. MacVane SH. Antimicrobial Resistance in the Intensive Care Unit: A Focus on Gram-Negative  
422 Bacterial Infections. *J Intensive Care Med*. 2017;32:25–37.
- 423 10. Prabaker K, Weinstein RA. Trends in antimicrobial resistance in intensive care units in the United  
424 States. *Curr Opin Crit Care*. 2011;17:472–9.
- 425 11. WHO | Tackling antimicrobial resistance in the COVID-19 pandemic [Internet]. WHO. World Health  
426 Organization; [cited 2020 Dec 3]. Available from: [http://www.who.int/bulletin/volumes/98/7/20-](http://www.who.int/bulletin/volumes/98/7/20-268573/en/)  
427 [268573/en/](http://www.who.int/bulletin/volumes/98/7/20-268573/en/)
- 428 12. Rawson TM, Ming D, Ahmad R, Moore LSP, Holmes AH. Antimicrobial use, drug-resistant infections  
429 and COVID-19. *Nature Reviews Microbiology*. Nature Publishing Group; 2020;18:409–10.
- 430 13. Rawson TM, Moore LSP, Castro-Sanchez E, Charani E, Davies F, Satta G, et al. COVID-19 and the  
431 potential long-term impact on antimicrobial resistance. *Journal of Antimicrobial Chemotherapy*.  
432 2020;75:1681–4.
- 433 14. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and  
434 fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial  
435 prescribing. *Clinical Infectious Diseases*. 2020;ciaa530.
- 436 15. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK  
437 patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective  
438 observational cohort study. *BMJ [Internet]*. British Medical Journal Publishing Group; 2020 [cited 2020  
439 Dec 3];369. Available from: <https://www.bmj.com/content/369/bmj.m1985>
- 440 16. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel  
441 coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill*. 2020;25.
- 442 17. Buehler PK, Zinkernagel AS, Hofmaenner DA, Wendel Garcia PD, Acevedo CT, Gómez-Mejía A, et  
443 al. Bacterial pulmonary superinfections are associated with longer duration of ventilation in critically  
444 ill COVID-19 patients. *Cell Reports Medicine*. 2021;2:100229.



- 445 18. Haigh J, Degun A, Eydmann M, Millar M, Wilks M. Improved Performance of Bacterium and Yeast  
446 Identification by a Commercial Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass  
447 Spectrometry System in the Clinical Microbiology Laboratory. *J Clin Microbiol.* 2011;49:3441–3441.
- 448 19. EUCAST Disk Diffusion Method for Antimicrobial Susceptibility Testing. Version 8.0 (January 2020).  
449 [https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\\_files/Disk\\_test\\_documents/2020\\_](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/2020_manuals/Manual_v_8.0_EUCAST_Disk_Test_2020.pdf)  
450 [manu](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/2020_manuals/Manual_v_8.0_EUCAST_Disk_Test_2020.pdf)  
[als/Manual\\_v\\_8.0\\_EUCAST\\_Disk\\_Test\\_2020.pdf](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/2020_manuals/Manual_v_8.0_EUCAST_Disk_Test_2020.pdf).
- 451 20. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for  
452 interpretation of MICs and zone diameters. Version 10.0, 2020.  
453 [https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\\_files/Breakpoint\\_tables/v\\_10.0\\_Breakp](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_10.0_Breakpoint_Tables.pdf)  
454 [oint\\_Tables.pdf](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_10.0_Breakpoint_Tables.pdf).
- 455 21. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for  
456 interpretation of MICs and zone diameters. Version 9.0, 2019.  
457 [https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\\_files/Breakpoint\\_tables/v\\_9.0\\_Breakpo](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_9.0_Breakpoint_Tables.pdf)  
458 [int\\_Tables.pdf](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_9.0_Breakpoint_Tables.pdf).
- 459 22. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI supplement  
460 M100. Wayne, PA: Clinical Laboratory Standards Institute; 2020.
- 461 23. CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically;  
462 Approved Standard—Ninth Edition. CLSI document M07-A9. Wayne, PA: Clinical and Laboratory  
463 Standards Institute; 2012.
- 464 24. FDA-Identified Interpretive Criteria for Plazomicin. [https://www.fda.gov/drugs/development-](https://www.fda.gov/drugs/development-resources/plazomicin-injection)  
465 [resources/plazomicin-injection](https://www.fda.gov/drugs/development-resources/plazomicin-injection). Accessed 16 December 2020.
- 466 25. Juhas M, Widlake E, Teo J, Huseby DL, Tyrrell JM, Polikanov YS, et al. *In vitro* activity of apramycin  
467 against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and *Acinetobacter*  
468 *baumannii*. *Journal of Antimicrobial Chemotherapy.* 2019;74:944–52.
- 469 26. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. :7.
- 470 27. McArthur AG, Waglechner N, Nizam F, Yan A, Azad MA, Baylay AJ, et al. The Comprehensive  
471 Antibiotic Resistance Database. *Antimicrob Agents Chemother.* 2013;57:3348–57.
- 472 28. Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Bouchard M, Edalatmand A, et al. CARD 2020:  
473 antibiotic resistome surveillance with the comprehensive antibiotic resistance database. *Nucleic Acids*  
474 *Research.* 2019;gkz935.
- 475 29. Jones RN. Microbial Etiologies of Hospital-Acquired Bacterial Pneumonia and Ventilator-  
476 Associated Bacterial Pneumonia. *CLIN INFECT DIS.* 2010;51:S81–7.
- 477 30. Zhu X, Ge Y, Wu T, Zhao K, Chen Y, Wu B, et al. Co-infection with respiratory pathogens among  
478 COVID-2019 cases. *Virus Res.* 2020;285:198005.
- 479 31. Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et  
480 al. Incidence of co-infections and superinfections in hospitalised patients with COVID-19: a  
481 retrospective cohort study. *Clinical Microbiology and Infection [Internet]. Elsevier; 2020 [cited 2020*  
482 *Aug 7];0.* Available from: [https://www.clinicalmicrobiologyandinfection.com/article/S1198-](https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30450-X/abstract)  
483 [743X\(20\)30450-X/abstract](https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30450-X/abstract)
- 484 32. Li J, Wang J, Yang Y, Cai P, Cao J, Cai X, et al. Etiology and antimicrobial resistance of secondary  
485 bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis.  
486 *Antimicrob Resist Infect Control.* 2020;9:153.
- 487 33. Rhodes KA, Schweizer HP. Antibiotic resistance in Burkholderia species. *Drug Resistance Updates.*  
488 2016;28:82–90.
- 489 34. Barbier F, Andremont A, Wolff M, Bouadma L. Hospital-acquired pneumonia and ventilator-  
490 associated pneumonia: recent advances in epidemiology and management. *Curr Opin Pulm Med.*  
491 2013;19:216–28.

- 492 35. Bhagirath AY, Li Y, Somayajula D, Dadashi M, Badr S, Duan K. Cystic fibrosis lung environment and  
493 *Pseudomonas aeruginosa* infection. *BMC Pulm Med*. 2016;16:174.
- 494 36. Horcajada JP, Montero M, Oliver A, Sorlí L, Luque S, Gómez-Zorrilla S, et al. Epidemiology and  
495 Treatment of Multidrug-Resistant and Extensively Drug-Resistant *Pseudomonas aeruginosa*  
496 Infections. *Clin Microbiol Reviews*. 2019;32:e00031-19, /cmr/32/4/CMR.00031-19.atom.
- 497 37. Li X-Z, Plésiat P, Nikaido H. The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-  
498 Negative Bacteria. *Clin Microbiol Rev*. 2015;28:337–418.
- 499 38. Contou D, Claudinon A, Pajot O, Micaëlo M, Longuet Flandre P, Dubert M, et al. Bacterial and viral  
500 co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. *Ann Intensive*  
501 *Care*. 2020;10:119.
- 502 39. Nori P, Szymczak W, Puius Y, Sharma A, Cowman K, Gialanella P, et al. Emerging Co-Pathogens:  
503 New Delhi Metallo-beta-lactamase producing Enterobacterales Infections in New York City COVID-19  
504 Patients. *Int J Antimicrob Agents*. 2020;56:106179.
- 505 40. Sharifipour E, Shams S, Esmkhani M, Khodadadi J, Fotouhi-Ardakani R, Koohpaei A, et al. Evaluation  
506 of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU. *BMC Infect*  
507 *Dis*. 2020;20:646.
- 508 41. Porretta AD, Baggiani A, Arzilli G, Casigliani V, Mariotti T, Mariottini F, et al. Increased Risk of  
509 Acquisition of New Delhi Metallo-Beta-Lactamase-Producing Carbapenem-Resistant Enterobacterales  
510 (NDM-CRE) among a Cohort of COVID-19 Patients in a Teaching Hospital in Tuscany, Italy. *Pathogens*.  
511 2020;9:E635.
- 512 42. Girlich D, Naas T, Nordmann P. Biochemical Characterization of the Naturally Occurring  
513 Oxacillinase OXA-50 of *Pseudomonas aeruginosa*. *AAC*. 2004;48:2043–8.
- 514 43. Berrazeg M, Jeannot K, Ntsogo Enguéné VY, Broutin I, Loeffert S, Fournier D, et al. Mutations in  $\beta$ -  
515 Lactamase AmpC Increase Resistance of *Pseudomonas aeruginosa* Isolates to Antipseudomonal  
516 Cephalosporins. *Antimicrob Agents Chemother*. 2015;59:6248–55.
- 517 44. Pan Y, Xu Y, Wang Z, Fang Y, Shen J. Overexpression of MexAB-OprM efflux pump in carbapenem-  
518 resistant *Pseudomonas aeruginosa*. *Arch Microbiol*. 2016;198:565–71.
- 519 45. López-Causapé C, Cabot G, del Barrio-Tofiño E, Oliver A. The Versatile Mutational Resistome of  
520 *Pseudomonas aeruginosa*. *Front Microbiol*. 2018;9:685.
- 521 46. Goldstein I, Wallet F, Robert J, Becquemin M-H, Marquette C-H, Rouby J-J. Lung tissue  
522 concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs. *Am*  
523 *J Respir Crit Care Med*. 2002;165:171–5.
- 524 47. Ioannidou E, Siempos II, Falagas ME. Administration of antimicrobials via the respiratory tract for  
525 the treatment of patients with nosocomial pneumonia: a meta-analysis. *J Antimicrob Chemother*.  
526 2007;60:1216–26.
- 527 48. Becker K, Aranzana-Climent V, Cao S, Nilsson A, Shariatgorji R, Haldimann K, et al. Efficacy of EBL-  
528 1003 (apramycin) against *Acinetobacter baumannii* lung infections in mice. *Clinical Microbiology and*  
529 *Infection* [Internet]. 2020 [cited 2020 Dec 14]; Available from:  
530 <http://www.sciencedirect.com/science/article/pii/S1198743X20307540>
- 531 49. Smith KP, Kirby JE. Evaluation of apramycin activity against carbapenem-resistant and -susceptible  
532 strains of Enterobacteriaceae. *Diagn Microbiol Infect Dis*. 2016;86:439–41.
- 533 50. Kang AD, Smith KP, Eliopoulos GM, Berg AH, McCoy C, Kirby JE. In vitro Apramycin Activity against  
534 multidrug-resistant *Acinetobacter baumannii* and *Pseudomonas aeruginosa*. *Diagnostic Microbiology*  
535 *and Infectious Disease*. 2017;88:188–91.
- 536